These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2439817)

  • 1. Effects of bopindolol on left ventricular function during exercise in patients with coronary artery disease.
    Righetti A; Mérier G; Viquerat C; Ratib O; Rutishauser W
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S39-41. PubMed ID: 2439817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic effects of bopindolol and atenolol in coronary artery disease. A noninvasive study.
    Rapola JM; Pellinen TJ; Toivonen L; Nieminen MS
    Ann Med; 1990; 22(4):221-4. PubMed ID: 2248757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of atenolol and bopindolol on circadian heart rate.
    Fitscha P; Meisner W; Tiso B
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S51-4. PubMed ID: 2439821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and long-term antihypertensive effect of bopindolol--a nonselective beta-adrenergic blocker with ISA.
    Andersson OK; Hedner T; Nyberg G
    Eur J Clin Pharmacol; 1985; 29(3):281-5. PubMed ID: 2866965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bopindolol in chronic stable angina pectoris: duration and extent of antianginal action.
    Carboni GP; Scardovi AB; D'Ermo M; Prati PL
    Br J Clin Pharmacol; 1991 Dec; 32(6):755-7. PubMed ID: 1685090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodynamic effects of short-term treatment with bopindolol in essential hypertension.
    Fitscha P; Meisner W; Brandstetter G; Tiso B
    Eur J Clin Pharmacol; 1988; 34(4):411-3. PubMed ID: 2900146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodynamic effects of atenolol and bopindolol at rest and during isometric exercise. A non-invasive study in healthy volunteers.
    Nieminen MS; Rapola J; Pellinen TJ; Toivonen L
    Ann Clin Res; 1988; 20(6):431-5. PubMed ID: 2905879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bopindolol on the circadian blood pressure profile in essential hypertension.
    Favre L; Adamec R; Boxho G
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S60-3. PubMed ID: 2439823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind comparison of once-daily bopindolol and atenolol for mild-to-moderate hypertension.
    Colnago R; Meregalli M; Turri D; Nazzari M; Fiorella G; Guffanti EE; Mazzola C
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):347-52. PubMed ID: 2887520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive efficacy of the new long-acting beta-blocker bopindolol as related to age.
    Hulthén UL; van Brummelen P; Amann FW; Bühler FR
    J Cardiovasc Pharmacol; 1983; 5(3):426-9. PubMed ID: 6191141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.
    Aellig WH
    Br J Clin Pharmacol; 1985 Jun; 19(6):775-81. PubMed ID: 2862891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effect of bopindolol: a multi-centre study.
    Török E; Szám I; Buday G; Kerkovits G; Farsang C; Hajtman B
    J Hum Hypertens; 1990 Aug; 4(4):458-60. PubMed ID: 1979635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive treatment with bopindolol alone or combined with a diuretic in general practice.
    Weidmann P; Bousquet JC
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S80-7. PubMed ID: 2439828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of nifedipine to maximal nitrate and beta-adrenoreceptor blocker therapy in coronary artery disease.
    White HD; Polak JF; Wynne J; Holman BL; Antman EM; Nesto RW
    Am J Cardiol; 1985 May; 55(11):1303-7. PubMed ID: 2859798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and long-term antihypertensive effect of bopindolol once daily or once weekly.
    Andersson O; Hedner T; Nyberg G
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S74-6. PubMed ID: 2439826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-finding study with bopindolol in arterial hypertension.
    Willimann P; Peter R; Siegenthaler H
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S25-9. PubMed ID: 2439814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.
    Grevel J
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S16-9. PubMed ID: 2439812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.
    Schiess W; Dorow P
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S30-3. PubMed ID: 2439815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bopindolol: a new long acting beta-receptor antagonist; its effects on haemodynamics, and on the renin response to tilting.
    Turner DR; Goodwin FJ; Knight AR; Littlejohns DW; Sharman VL; Vere DW
    Br J Clin Pharmacol; 1984 Mar; 17(3):295-9. PubMed ID: 6143566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the acute haemodynamic effects of bopindolol and propranolol at rest and during supine exercise.
    Fitscha P; Meisner W; Tiso B
    Eur J Clin Pharmacol; 1988; 34(4):359-62. PubMed ID: 2900143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.